Copyright Reports & Markets. All rights reserved.

Global Respiratory Antivirals Market Size, Status and Forecast 2020-2026

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Key Market Segments
  • 1.3 Players Covered: Ranking by Respiratory Antivirals Revenue
  • 1.4 Market Analysis by Type
    • 1.4.1 Global Respiratory Antivirals Market Size Growth Rate by Type: 2020 VS 2026
    • 1.4.2 Nucleoside Analogs
    • 1.4.3 Neuraminidase Inhibitors
    • 1.4.4 Ion Channel Blockers
    • 1.4.5 Fusion Protein Inhibitors
  • 1.5 Market by Application
    • 1.5.1 Global Respiratory Antivirals Market Share by Application: 2020 VS 2026
    • 1.5.2 Upper Respiratory Tract Infections (URTIs)
    • 1.5.3 Influenza
    • 1.5.4 Bronchiolitis
    • 1.5.5 Pneumonia
    • 1.5.6 Measles
    • 1.5.7 Others
  • 1.6 Study Objectives
  • 1.7 Years Considered

2 Global Growth Trends by Regions

  • 2.1 Respiratory Antivirals Market Perspective (2015-2026)
  • 2.2 Respiratory Antivirals Growth Trends by Regions
    • 2.2.1 Respiratory Antivirals Market Size by Regions: 2015 VS 2020 VS 2026
    • 2.2.2 Respiratory Antivirals Historic Market Share by Regions (2015-2020)
    • 2.2.3 Respiratory Antivirals Forecasted Market Size by Regions (2021-2026)
  • 2.3 Industry Trends and Growth Strategy
    • 2.3.1 Market Top Trends
    • 2.3.2 Market Drivers
    • 2.3.3 Market Challenges
    • 2.3.4 Porter’s Five Forces Analysis
    • 2.3.5 Respiratory Antivirals Market Growth Strategy
    • 2.3.6 Primary Interviews with Key Respiratory Antivirals Players (Opinion Leaders)

3 Competition Landscape by Key Players

  • 3.1 Global Top Respiratory Antivirals Players by Market Size
    • 3.1.1 Global Top Respiratory Antivirals Players by Revenue (2015-2020)
    • 3.1.2 Global Respiratory Antivirals Revenue Market Share by Players (2015-2020)
    • 3.1.3 Global Respiratory Antivirals Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.2 Global Respiratory Antivirals Market Concentration Ratio
    • 3.2.1 Global Respiratory Antivirals Market Concentration Ratio (CR5 and HHI)
    • 3.2.2 Global Top 10 and Top 5 Companies by Respiratory Antivirals Revenue in 2019
  • 3.3 Respiratory Antivirals Key Players Head office and Area Served
  • 3.4 Key Players Respiratory Antivirals Product Solution and Service
  • 3.5 Date of Enter into Respiratory Antivirals Market
  • 3.6 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type (2015-2026)

  • 4.1 Global Respiratory Antivirals Historic Market Size by Type (2015-2020)
  • 4.2 Global Respiratory Antivirals Forecasted Market Size by Type (2021-2026)

5 Respiratory Antivirals Breakdown Data by Application (2015-2026)

  • 5.1 Global Respiratory Antivirals Market Size by Application (2015-2020)
  • 5.2 Global Respiratory Antivirals Forecasted Market Size by Application (2021-2026)

6 North America

  • 6.1 North America Respiratory Antivirals Market Size (2015-2020)
  • 6.2 Respiratory Antivirals Key Players in North America (2019-2020)
  • 6.3 North America Respiratory Antivirals Market Size by Type (2015-2020)
  • 6.4 North America Respiratory Antivirals Market Size by Application (2015-2020)

7 Europe

  • 7.1 Europe Respiratory Antivirals Market Size (2015-2020)
  • 7.2 Respiratory Antivirals Key Players in Europe (2019-2020)
  • 7.3 Europe Respiratory Antivirals Market Size by Type (2015-2020)
  • 7.4 Europe Respiratory Antivirals Market Size by Application (2015-2020)

8 China

  • 8.1 China Respiratory Antivirals Market Size (2015-2020)
  • 8.2 Respiratory Antivirals Key Players in China (2019-2020)
  • 8.3 China Respiratory Antivirals Market Size by Type (2015-2020)
  • 8.4 China Respiratory Antivirals Market Size by Application (2015-2020)

(2015-2020)

    (2015-2020)

      9 Key Players Profiles

      • 9.1 GSK
        • 9.1.1 GSK Company Details
        • 9.1.2 GSK Business Overview and Its Total Revenue
        • 9.1.3 GSK Respiratory Antivirals Introduction
        • 9.1.4 GSK Revenue in Respiratory Antivirals Business (2015-2020))
        • 9.1.5 GSK Recent Development
      • 9.2 Boehringer Ingelheim
        • 9.2.1 Boehringer Ingelheim Company Details
        • 9.2.2 Boehringer Ingelheim Business Overview and Its Total Revenue
        • 9.2.3 Boehringer Ingelheim Respiratory Antivirals Introduction
        • 9.2.4 Boehringer Ingelheim Revenue in Respiratory Antivirals Business (2015-2020)
        • 9.2.5 Boehringer Ingelheim Recent Development
      • 9.3 AstraZeneca
        • 9.3.1 AstraZeneca Company Details
        • 9.3.2 AstraZeneca Business Overview and Its Total Revenue
        • 9.3.3 AstraZeneca Respiratory Antivirals Introduction
        • 9.3.4 AstraZeneca Revenue in Respiratory Antivirals Business (2015-2020)
        • 9.3.5 AstraZeneca Recent Development
      • 9.4 Merck
        • 9.4.1 Merck Company Details
        • 9.4.2 Merck Business Overview and Its Total Revenue
        • 9.4.3 Merck Respiratory Antivirals Introduction
        • 9.4.4 Merck Revenue in Respiratory Antivirals Business (2015-2020)
        • 9.4.5 Merck Recent Development
      • 9.5 Novartis
        • 9.5.1 Novartis Company Details
        • 9.5.2 Novartis Business Overview and Its Total Revenue
        • 9.5.3 Novartis Respiratory Antivirals Introduction
        • 9.5.4 Novartis Revenue in Respiratory Antivirals Business (2015-2020)
        • 9.5.5 Novartis Recent Development
      • 9.6 Beximco Pharmaceuticals
        • 9.6.1 Beximco Pharmaceuticals Company Details
        • 9.6.2 Beximco Pharmaceuticals Business Overview and Its Total Revenue
        • 9.6.3 Beximco Pharmaceuticals Respiratory Antivirals Introduction
        • 9.6.4 Beximco Pharmaceuticals Revenue in Respiratory Antivirals Business (2015-2020)
        • 9.6.5 Beximco Pharmaceuticals Recent Development
      • 9.7 Pfizer
        • 9.7.1 Pfizer Company Details
        • 9.7.2 Pfizer Business Overview and Its Total Revenue
        • 9.7.3 Pfizer Respiratory Antivirals Introduction
        • 9.7.4 Pfizer Revenue in Respiratory Antivirals Business (2015-2020)
        • 9.7.5 Pfizer Recent Development
      • 9.8 Roche
        • 9.8.1 Roche Company Details
        • 9.8.2 Roche Business Overview and Its Total Revenue
        • 9.8.3 Roche Respiratory Antivirals Introduction
        • 9.8.4 Roche Revenue in Respiratory Antivirals Business (2015-2020)
        • 9.8.5 Roche Recent Development
      • 9.9 Bristol-Myers Squibb Company
        • 9.9.1 Bristol-Myers Squibb Company Company Details
        • 9.9.2 Bristol-Myers Squibb Company Business Overview and Its Total Revenue
        • 9.9.3 Bristol-Myers Squibb Company Respiratory Antivirals Introduction
        • 9.9.4 Bristol-Myers Squibb Company Revenue in Respiratory Antivirals Business (2015-2020)
        • 9.9.5 Bristol-Myers Squibb Company Recent Development
      • 9.10 Johnson & Johnson
        • 9.10.1 Johnson & Johnson Company Details
        • 9.10.2 Johnson & Johnson Business Overview and Its Total Revenue
        • 9.10.3 Johnson & Johnson Respiratory Antivirals Introduction
        • 9.10.4 Johnson & Johnson Revenue in Respiratory Antivirals Business (2015-2020)
        • 9.10.5 Johnson & Johnson Recent Development
      • 9.11 AbbVie Inc.
        • 10.11.1 AbbVie Inc. Company Details
        • 10.11.2 AbbVie Inc. Business Overview and Its Total Revenue
        • 10.11.3 AbbVie Inc. Respiratory Antivirals Introduction
        • 10.11.4 AbbVie Inc. Revenue in Respiratory Antivirals Business (2015-2020)
        • 10.11.5 AbbVie Inc. Recent Development
      • 9.12 Sanofi
        • 10.12.1 Sanofi Company Details
        • 10.12.2 Sanofi Business Overview and Its Total Revenue
        • 10.12.3 Sanofi Respiratory Antivirals Introduction
        • 10.12.4 Sanofi Revenue in Respiratory Antivirals Business (2015-2020)
        • 10.12.5 Sanofi Recent Development

      10 Analyst's Viewpoints/Conclusions

        11 Appendix

        • 11.1 Research Methodology
          • 11.1.1 Methodology/Research Approach
          • 11.1.2 Data Source
        • 11.2 Disclaimer

        This report focuses on the global Respiratory Antivirals status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Respiratory Antivirals development in North America, Europe and China.

        The key players covered in this study
        GSK
        Boehringer Ingelheim
        AstraZeneca
        Merck
        Novartis
        Beximco Pharmaceuticals
        Pfizer
        Roche
        Bristol-Myers Squibb Company
        Johnson & Johnson
        AbbVie Inc.
        Sanofi

        Market segment by Type, the product can be split into
        Nucleoside Analogs
        Neuraminidase Inhibitors
        Ion Channel Blockers
        Fusion Protein Inhibitors
        Market segment by Application, split into
        Upper Respiratory Tract Infections (URTIs)
        Influenza
        Bronchiolitis
        Pneumonia
        Measles
        Others

        Market segment by Regions/Countries, this report covers
        North America
        Europe
        China

        The study objectives of this report are:
        To analyze global Respiratory Antivirals status, future forecast, growth opportunity, key market and key players.
        To present the Respiratory Antivirals development in North America, Europe and China.
        To strategically profile the key players and comprehensively analyze their development plan and strategies.
        To define, describe and forecast the market by type, market and key regions.

        In this study, the years considered to estimate the market size of Respiratory Antivirals are as follows:
        History Year: 2015-2019
        Base Year: 2019
        Estimated Year: 2020
        Forecast Year 2020 to 2026
        For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

        Buy now